SAN DIEGO, October 15, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Hubert Chen, M.D., Chief Medical Officer, will present at the H.C. Wainwright 2019 NASH Investor Conference on Monday, October 21, 2019 at 2:20 p.m. EDT (11:20 a.m. PDT) in New York City.
About Metacrine
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.
Contacts:
Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com